Analyst Zbigniew Budzinski upgraded Incyte to Hold, setting a fair value of $112.19 per share, just 4% below the current market price. This upgrade follows encouraging Phase 1 trial data for KRAS G12D and TGFβR2×PD-1, which increase the likelihood of drug approvals. Incyte's Q3 net sales grew 14% year-over-year, with raised guidance for Opzelura and hematology/oncology products, while Jakafi guidance remains steady. Despite risks from early-stage data and upcoming Phase 3 results, improved cash flow and pipeline progress support the rating change.
Incyte shares trade at USD 119.20 on Pluang as of Oct 30, 2026 13:32 WIB, slightly above the analyst's fair value estimate of $112.19. The stock has gained 2.05% in the past day, reflecting some positive momentum. Despite this, Pluang order activity shows 100% sell interest, indicating cautious sentiment among investors.
